Free Trial
OTCMKTS:HLUYY

H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

H. Lundbeck A/S logo
$22.00 -0.01 (-0.02%)
As of 08/9/2022

About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)

Key Stats

Today's Range
$22.00
$24.00
50-Day Range
$22.00
$22.00
52-Week Range
$10.00
$31.55
Volume
7,500 shs
Average Volume
1,758 shs
Market Capitalization
$21.91 billion
P/E Ratio
25.00
Dividend Yield
0.91%
Price Target
N/A
Consensus Rating
N/A

Company Overview

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

HLUYY Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
H Lundbeck AS (LUNAM)
H. Lundbeck A/S (HLBBF)
See More Headlines

HLUYY Stock Analysis - Frequently Asked Questions

H. Lundbeck A/S's stock was trading at $22.00 at the start of the year. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00.
View the best growth stocks for 2025 here
.

H. Lundbeck A/S (OTCMKTS:HLUYY) released its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.16. The firm earned $547.05 million during the quarter, compared to analysts' expectations of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%.

H. Lundbeck A/S subsidiaries include Alder BioPharmaceuticals, and Prexton Therapeutics.

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/04/2015
Today
5/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Private Households
Sub-Industry
N/A
Current Symbol
OTCMKTS:HLUYY
CIK
N/A
Employees
5,348
Year Founded
1915

Profitability

Trailing P/E Ratio
25.00
Forward P/E Ratio
10.48
P/E Growth
N/A
Net Income
$209.69 million
Pretax Margin
7.83%

Debt

Sales & Book Value

Annual Sales
$2.59 billion
Cash Flow
$3.36 per share
Price / Cash Flow
6.54
Book Value
$14.60 per share
Price / Book
1.51

Miscellaneous

Free Float
N/A
Market Cap
$21.91 billion
Optionable
Not Optionable
Beta
0.68

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:HLUYY) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners